PL1848813T3 - Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d - Google Patents

Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d

Info

Publication number
PL1848813T3
PL1848813T3 PL06733921T PL06733921T PL1848813T3 PL 1848813 T3 PL1848813 T3 PL 1848813T3 PL 06733921 T PL06733921 T PL 06733921T PL 06733921 T PL06733921 T PL 06733921T PL 1848813 T3 PL1848813 T3 PL 1848813T3
Authority
PL
Poland
Prior art keywords
cd1d
nkt cells
restricted nkt
activation
bacterial glycolipid
Prior art date
Application number
PL06733921T
Other languages
English (en)
Inventor
Luc Teyton
Albert Bendelac
Paul Savage
Original Assignee
Univ Brigham Young
Scripps Research Inst
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brigham Young, Scripps Research Inst, Univ Chicago filed Critical Univ Brigham Young
Publication of PL1848813T3 publication Critical patent/PL1848813T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06733921T 2005-01-28 2006-01-26 Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d PL1848813T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28
PCT/US2006/002781 WO2006083671A2 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells
EP06733921.8A EP1848813B1 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells

Publications (1)

Publication Number Publication Date
PL1848813T3 true PL1848813T3 (pl) 2013-09-30

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06733921T PL1848813T3 (pl) 2005-01-28 2006-01-26 Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d

Country Status (12)

Country Link
US (1) US9295722B2 (pl)
EP (1) EP1848813B1 (pl)
JP (1) JP5053101B2 (pl)
AU (1) AU2006211485B2 (pl)
BR (1) BRPI0607299A2 (pl)
CA (1) CA2593715C (pl)
DK (1) DK1848813T3 (pl)
ES (1) ES2423005T3 (pl)
PL (1) PL1848813T3 (pl)
PT (1) PT1848813E (pl)
WO (1) WO2006083671A2 (pl)
ZA (1) ZA200706208B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
JP2010523724A (ja) * 2007-04-13 2010-07-15 アカデミア シニカ α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
WO2009101475A2 (en) * 2007-12-05 2009-08-20 Wittycell S.A.S. Compositions for and methods of enhancing the immune response to antigens
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物
CN102935080A (zh) 2009-02-25 2013-02-20 休普拉特克药品有限公司 苯达莫司汀环多糖组合物
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2014088432A1 (en) * 2012-12-06 2014-06-12 Callaghan Innovation Research Limited Conjugate compounds
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
EP4138849A4 (en) * 2020-04-23 2024-04-17 The Regents of the University of California CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF INKT LYMPHOCYTES
KR20230119224A (ko) * 2020-12-18 2023-08-16 로레알 스핑고모나스 속 박테리아 추출물
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2024107463A1 (en) * 2022-11-14 2024-05-23 The Trustees Of Columbia University In The City Of New York 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pl) 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
CA2160566C (en) 1993-04-15 2004-07-13 Tatsuo Higa Novel sphingoglycolipids and uses thereof
WO1994026760A1 (en) 1993-05-14 1994-11-24 Cytel Corporation SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
CN1222293C (zh) 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α－糖基神经酰胺的NKT细胞活化剂
WO1999012562A1 (en) * 1997-09-12 1999-03-18 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
WO2001082935A1 (fr) 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedes contre le cancer
AU2002213588A1 (en) * 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
AU2001268564A1 (en) * 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) * 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
WO2003039568A1 (fr) 2001-11-06 2003-05-15 Orient Cancer Therary Co.,Ltd. Compositions anticancereuses
AU2003251518B2 (en) * 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
CA2519568C (en) 2003-03-20 2012-01-03 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
AU2005282684B9 (en) 2004-09-03 2011-07-07 Brigham Young University Methods of activating NKT cells
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use

Also Published As

Publication number Publication date
WO2006083671A3 (en) 2007-02-22
US20080279894A1 (en) 2008-11-13
ES2423005T3 (es) 2013-09-17
PT1848813E (pt) 2013-07-15
DK1848813T3 (da) 2013-07-15
EP1848813A4 (en) 2008-07-09
BRPI0607299A2 (pt) 2009-08-25
CA2593715A1 (en) 2006-08-10
WO2006083671A2 (en) 2006-08-10
AU2006211485A1 (en) 2006-08-10
WO2006083671B1 (en) 2007-04-12
AU2006211485B2 (en) 2011-04-14
JP2008528608A (ja) 2008-07-31
JP5053101B2 (ja) 2012-10-17
CA2593715C (en) 2015-05-05
US9295722B2 (en) 2016-03-29
EP1848813A2 (en) 2007-10-31
ZA200706208B (en) 2008-04-30
EP1848813B1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
PL1848813T3 (pl) Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d
EP1889172A4 (en) SYSTEM FOR SENDING MESSAGES SPECIFIC TO PATIENTS
SG10201510384UA (en) Cell culture improvements
IL205143A0 (en) Novel sulfated oligosaccharide derivatives
EP1844380B8 (en) Improvements in or relating to ablutionary installations
GB0605450D0 (en) Cell co-culture
EP2272854A4 (en) NEW GLYCOLIPID AND USE THEREOF
ZA200708100B (en) Oligosaccharide mixture
ZA201007022B (en) Carbohydrate gel
GB0613756D0 (en) Cell culture medium
EP2154234A4 (en) TRANSPARENT SOLID SOAP
GB0715183D0 (en) Surfactants not toxic to bacteria
EP2069477A4 (en) CHEMICAL REPULSION OF CELLS
GB2438352B (en) Cell culture chamber
GB0517382D0 (en) Cell culture
EP1899910A4 (en) USING MESSAGES TO ENHANCE CRM FUNCTIONALITY
EP2185684B8 (de) Kollagenhaltiger zellträger
GB0523950D0 (en) Bioreactor system
SI1848813T1 (sl) Aktiviranje bakterijskega glikopida s CD1D omenjenih NKT-celic
GB0606671D0 (en) Cell Culture
GB0609797D0 (en) Adhesive solution for application to the skin
GB0509318D0 (en) TCR-independent activation of T cells
EP1716857A4 (en) COMPOSITION FOR ACTIVATION OF NKT CELLS
GB0522564D0 (en) Cells
GB0605180D0 (en) Transfected cells